SICURANZA ANNA

Anna
Sicuranza
Ricercatore Legge 240/10 - tempo determinato

Attività didattica

Attività di ricerca

Ultime pubblicazioni:

  • Minetto, P., Candoni, A., Guolo, F., Clavio, M., Zannier, M.E., Miglino, M., et al. (2021). Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic Burden. CANCERS, 13(1), 1-13. - dettaglio
  • Caocci, G., Mulas, O., Capodanno, I., Bonifacio, M., Annunziata, M., Galimberti, S., et al. (2021). Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. ANNALS OF HEMATOLOGY. - dettaglio
  • Bacchiarri, F., Sammartano, V., Santoni, A., Raspadori, D., Zappone, E., Defina, M., et al. (2021). First reported case of secondary mixed phenotype acute leukemia after multiple myeloma. AMERICAN JOURNAL OF BLOOD RESEARCH, 11(1), 123-131. - dettaglio
  • Cencini, E., Fabbri, A., Sicuranza, A., Gozzetti, A., & Bocchia, M. (2021). The role of tumor-associated macrophages in hematologic malignancies. CANCERS, 13(14), 1-23 [10.3390/cancers13143597]. - dettaglio
  • Gozzetti, A., Bacchiarri, F., Sammartano, V., Defina, M., Sicuranza, A., Mecacci, B., et al. (2020). Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. FRONTIERS IN ONCOLOGY, 10, 1-6 [10.3389/fonc.2020.570187]. - dettaglio